Drug intelligence / Profile preview

extended-release epidural morphine

Development stage
Phase 4
Lead developer
Endo International
Modality
Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
Administration
Epidural
01

Overview

Extended-release epidural morphine is a single-dose, lipid-encapsulated formulation of morphine sulfate designed for administration into the lumbar epidural space. It provides prolonged postoperative analgesia for up to 48 hours after injection. The drug acts as an opioid agonist at the mu-opioid receptor in the central nervous system, altering pain perception and response. Extended-release technology allows for sustained release and longer duration of action compared to standard formulations. It is primarily indicated for pain management following major surgeries such as hip arthroplasty, lower abdominal surgery (including cesarean section), and lower extremity procedures associated with moderate-to-severe pain[3][4][5][7]. The formulation reduces the need for continuous infusions or repeated dosing but carries risks typical of opioids—including respiratory depression and pruritus—at higher rates than some alternative modalities[5][7].

Brand names
DepoDur
Other names
extended-release epidural morphineEREMlipid-encapsulated extended-release epidural morphine
02

Targets

MOR (Mu opioid receptor)

Beyond the preview

Go deeper on extended-release epidural morphine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on extended-release epidural morphine.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call